Deerfield Management Company, L.P. (Series C) Rocket Pharmaceuticals, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$12.37 - $18.41 $10.8 Million - $16 Million	870,000 New	870,000 $13.9 Million
Q3 2020 Nov 16, 2020	SELL	$20.5 - $28.59 $1.09 Million - $1.52 Million	-53,043 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$13.32 - $22.61 $21.6 Million - $36.7 Million	-1,624,324 Reduced 96.84%	53,043 $1.11 Million
Q1 2020 May 15, 2020	SELL	$9.71 - $25.11 $4.73 Million - $12.2 Million	-487,104 Reduced 22.5%	1,677,367 $23.4 Million
Q4 2019 Feb 14, 2020	BUY	$11.07 - $24.23 $4.32 Million - $9.46 Million	390,533 Added 22.02%	2,164,471 $49.3 Million
Q3 2019 Nov 14, 2019	BUY	$10.85 - $14.78 $6.91 Million - $9.41 Million	636,796 Added 56.0%	1,773,938 $20.7 Million
Q2 2019 Aug 14, 2019	BUY	$15.0 - $19.81 $12.9 Million - $17 Million	857,142 Added 306.12%	1,137,142 $17.1 Million
Q2 2018 Aug 14, 2018	SELL	$14.58 - $23.0 $1.75 Million - $2.76 Million	-120,000 Reduced 30.0%	280,000 $5.5 Million
Q1 2018 May 15, 2018	BUY	$11.68 - $19.19 $4.67 Million - $7.68 Million	400,000 New	400,000 $7.5 Million

Others Institutions Holding RCKT

# of Institutions

209

Shares Held

93.1M

Call Options Held

319K

Put Options Held

70.3K

Rtw Investments, LP New York, NY

17.7M
Shares

$189 Million
5.21% of portfolio
Wellington Management Group LLP Boston, MA

11.2M
Shares

$120 Million
0.04% of portfolio
Black Rock Inc. New York, NY

6.19M
Shares

$66.2 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

5.54M
Shares

$59.2 Million
0.0% of portfolio
Westfield Capital Management CO LP Boston, MA

4.49M
Shares

$48 Million
0.39% of portfolio

View Full List

About ROCKET PHARMACEUTICALS, INC.

Ticker RCKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 75,683,696
Market Cap $809M
Description
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...

More about RCKT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account